Platinum-sensitive recurrence in ovarian cancer: The role of tumor microenvironment

Jeremy Chien, Rui Kuang, Charles Landen, Viji Shridhar

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Despite several advances in the understanding of ovarian cancer pathobiology, in terms of driver genetic alterations in high-grade serous cancer, histologic heterogeneity of epithelial ovarian cancer, cell-of-origin for ovarian cancer, the survival rate from ovarian cancer is disappointingly low when compared to that of breast or prostate cancer. One of the factors contributing to the poor survival rate from ovarian cancer is the development of chemotherapy resistance following several rounds of chemotherapy. Although unicellular drug resistance mechanisms contribute to chemotherapy resistance, tumor microenvironment and the extracellular matrix (ECM), in particular, is emerging as a significant determinant of a tumor's response to chemotherapy. In this review, we discuss the potential role of the tumor microenvironment in ovarian cancer recurrence and resistance to chemotherapy. Finally, we propose an alternative view of platinum-sensitive recurrence to describe a potential role of the ECM in the process.

Original languageEnglish (US)
Article numberArticle 251
JournalFrontiers in Oncology
Volume3 SEP
DOIs
StatePublished - Dec 31 2013
Externally publishedYes

Fingerprint

Tumor Microenvironment
Platinum
Ovarian Neoplasms
Recurrence
Drug Therapy
Extracellular Matrix
Drug Resistance
Neoplasms
Prostatic Neoplasms
Breast Neoplasms

Keywords

  • Cancer stem cell
  • Extracellular matrix
  • Ovarian cancer
  • Platinum resistance
  • Platinum-sensitive recurrence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Platinum-sensitive recurrence in ovarian cancer : The role of tumor microenvironment. / Chien, Jeremy; Kuang, Rui; Landen, Charles; Shridhar, Viji.

In: Frontiers in Oncology, Vol. 3 SEP, Article 251, 31.12.2013.

Research output: Contribution to journalArticle

@article{60fb8223fc5d4cf092553cf0933a3dbe,
title = "Platinum-sensitive recurrence in ovarian cancer: The role of tumor microenvironment",
abstract = "Despite several advances in the understanding of ovarian cancer pathobiology, in terms of driver genetic alterations in high-grade serous cancer, histologic heterogeneity of epithelial ovarian cancer, cell-of-origin for ovarian cancer, the survival rate from ovarian cancer is disappointingly low when compared to that of breast or prostate cancer. One of the factors contributing to the poor survival rate from ovarian cancer is the development of chemotherapy resistance following several rounds of chemotherapy. Although unicellular drug resistance mechanisms contribute to chemotherapy resistance, tumor microenvironment and the extracellular matrix (ECM), in particular, is emerging as a significant determinant of a tumor's response to chemotherapy. In this review, we discuss the potential role of the tumor microenvironment in ovarian cancer recurrence and resistance to chemotherapy. Finally, we propose an alternative view of platinum-sensitive recurrence to describe a potential role of the ECM in the process.",
keywords = "Cancer stem cell, Extracellular matrix, Ovarian cancer, Platinum resistance, Platinum-sensitive recurrence",
author = "Jeremy Chien and Rui Kuang and Charles Landen and Viji Shridhar",
year = "2013",
month = "12",
day = "31",
doi = "10.3389/fonc.2013.00251",
language = "English (US)",
volume = "3 SEP",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Platinum-sensitive recurrence in ovarian cancer

T2 - The role of tumor microenvironment

AU - Chien, Jeremy

AU - Kuang, Rui

AU - Landen, Charles

AU - Shridhar, Viji

PY - 2013/12/31

Y1 - 2013/12/31

N2 - Despite several advances in the understanding of ovarian cancer pathobiology, in terms of driver genetic alterations in high-grade serous cancer, histologic heterogeneity of epithelial ovarian cancer, cell-of-origin for ovarian cancer, the survival rate from ovarian cancer is disappointingly low when compared to that of breast or prostate cancer. One of the factors contributing to the poor survival rate from ovarian cancer is the development of chemotherapy resistance following several rounds of chemotherapy. Although unicellular drug resistance mechanisms contribute to chemotherapy resistance, tumor microenvironment and the extracellular matrix (ECM), in particular, is emerging as a significant determinant of a tumor's response to chemotherapy. In this review, we discuss the potential role of the tumor microenvironment in ovarian cancer recurrence and resistance to chemotherapy. Finally, we propose an alternative view of platinum-sensitive recurrence to describe a potential role of the ECM in the process.

AB - Despite several advances in the understanding of ovarian cancer pathobiology, in terms of driver genetic alterations in high-grade serous cancer, histologic heterogeneity of epithelial ovarian cancer, cell-of-origin for ovarian cancer, the survival rate from ovarian cancer is disappointingly low when compared to that of breast or prostate cancer. One of the factors contributing to the poor survival rate from ovarian cancer is the development of chemotherapy resistance following several rounds of chemotherapy. Although unicellular drug resistance mechanisms contribute to chemotherapy resistance, tumor microenvironment and the extracellular matrix (ECM), in particular, is emerging as a significant determinant of a tumor's response to chemotherapy. In this review, we discuss the potential role of the tumor microenvironment in ovarian cancer recurrence and resistance to chemotherapy. Finally, we propose an alternative view of platinum-sensitive recurrence to describe a potential role of the ECM in the process.

KW - Cancer stem cell

KW - Extracellular matrix

KW - Ovarian cancer

KW - Platinum resistance

KW - Platinum-sensitive recurrence

UR - http://www.scopus.com/inward/record.url?scp=84888065590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888065590&partnerID=8YFLogxK

U2 - 10.3389/fonc.2013.00251

DO - 10.3389/fonc.2013.00251

M3 - Article

AN - SCOPUS:84888065590

VL - 3 SEP

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - Article 251

ER -